Teva upgraded to Neutral from Sell at Goldman

Goldman upgraded Teva to Neutral from Sell citing expectations that the narrative surrounding the company will now focus on growth and optionality in its underlying business. The firm raised its price target on shares to $52 from $40 and removed the stock from the Americas Sell List.

View Comments (0)